NEW YORK (GenomeWeb) – Trovagene today announced a collaboration with City of Hope to explore the clinical utility of the company's Precision Cancer Monitoring platform for detecting and monitoring EGFR mutations in lung cancer patients.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.